vs
Side-by-side financial comparison of Hologic (HOLX) and IDEX Corporation (IEX). Click either name above to swap in a different company.
Hologic is the larger business by last-quarter revenue ($1.0B vs $398.4M, roughly 2.6× IDEX Corporation). IDEX Corporation runs the higher net margin — 30.1% vs 17.1%, a 13.0% gap on every dollar of revenue. On growth, IDEX Corporation posted the faster year-over-year revenue change (16.7% vs 2.5%). Hologic produced more free cash flow last quarter ($215.2M vs $86.0M). Over the past eight quarters, Hologic's revenue compounded faster (1.5% CAGR vs -29.4%).
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
IDEX can refer to several things, including:International Defence Exhibition, a biennial arms and defense technology sales exhibition IDEX Corporation, a publicly listed company that makes fluidics systems and specialty engineered products Ideanomics, a publicly traded company that trades under the IDEX ticker symbol.
HOLX vs IEX — Head-to-Head
Income Statement — Q1 FY2026 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.0B | $398.4M |
| Net Profit | $179.1M | $120.0M |
| Gross Margin | 56.0% | 99.9% |
| Operating Margin | 22.6% | 43.3% |
| Net Margin | 17.1% | 30.1% |
| Revenue YoY | 2.5% | 16.7% |
| Net Profit YoY | -10.9% | 25.7% |
| EPS (diluted) | $0.79 | $1.61 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 26 | — | $398.4M | ||
| Q1 26 | — | $407.7M | ||
| Q4 25 | $1.0B | $899.1M | ||
| Q3 25 | $1.0B | $878.7M | ||
| Q2 25 | $1.0B | $865.4M | ||
| Q1 25 | $1.0B | $814.3M | ||
| Q4 24 | $1.0B | $862.9M | ||
| Q3 24 | $988.0M | $798.2M |
| Q2 26 | — | $120.0M | ||
| Q1 26 | — | $128.3M | ||
| Q4 25 | $179.1M | $128.3M | ||
| Q3 25 | $187.2M | $127.8M | ||
| Q2 25 | $194.9M | $131.6M | ||
| Q1 25 | $-17.4M | $95.5M | ||
| Q4 24 | $201.0M | $123.2M | ||
| Q3 24 | $178.6M | $119.1M |
| Q2 26 | — | 99.9% | ||
| Q1 26 | — | 94.9% | ||
| Q4 25 | 56.0% | 43.1% | ||
| Q3 25 | 55.6% | 44.5% | ||
| Q2 25 | 56.3% | 45.3% | ||
| Q1 25 | 37.5% | 45.3% | ||
| Q4 24 | 56.8% | 42.5% | ||
| Q3 24 | 56.4% | 44.3% |
| Q2 26 | — | 43.3% | ||
| Q1 26 | — | 45.0% | ||
| Q4 25 | 22.6% | 20.4% | ||
| Q3 25 | 22.6% | 21.1% | ||
| Q2 25 | 24.9% | 21.7% | ||
| Q1 25 | -0.7% | 17.4% | ||
| Q4 24 | 22.5% | 19.2% | ||
| Q3 24 | 23.3% | 21.0% |
| Q2 26 | — | 30.1% | ||
| Q1 26 | — | 31.5% | ||
| Q4 25 | 17.1% | 14.3% | ||
| Q3 25 | 17.8% | 14.5% | ||
| Q2 25 | 19.0% | 15.2% | ||
| Q1 25 | -1.7% | 11.7% | ||
| Q4 24 | 19.7% | 14.3% | ||
| Q3 24 | 18.1% | 14.9% |
| Q2 26 | — | $1.61 | ||
| Q1 26 | — | $1.71 | ||
| Q4 25 | $0.79 | $1.71 | ||
| Q3 25 | $0.84 | $1.70 | ||
| Q2 25 | $0.86 | $1.74 | ||
| Q1 25 | $-0.08 | $1.26 | ||
| Q4 24 | $0.87 | $1.61 | ||
| Q3 24 | $0.75 | $1.57 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.4B | $586.2M |
| Total DebtLower is stronger | $2.5B | — |
| Stockholders' EquityBook value | $5.2B | $4.0B |
| Total Assets | $9.2B | $6.9B |
| Debt / EquityLower = less leverage | 0.48× | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 26 | — | $586.2M | ||
| Q1 26 | — | $580.0M | ||
| Q4 25 | $2.4B | $580.0M | ||
| Q3 25 | $2.2B | $593.8M | ||
| Q2 25 | $1.9B | $568.2M | ||
| Q1 25 | $1.6B | $594.1M | ||
| Q4 24 | $2.0B | $620.8M | ||
| Q3 24 | $2.3B | $633.2M |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | $2.5B | $1.8B | ||
| Q3 25 | $2.5B | $1.9B | ||
| Q2 25 | $2.5B | $1.9B | ||
| Q1 25 | $2.5B | $2.0B | ||
| Q4 24 | $2.5B | $2.0B | ||
| Q3 24 | $2.5B | $2.1B |
| Q2 26 | — | $4.0B | ||
| Q1 26 | — | $4.0B | ||
| Q4 25 | $5.2B | $4.0B | ||
| Q3 25 | $5.0B | $4.0B | ||
| Q2 25 | $4.8B | $4.0B | ||
| Q1 25 | $4.6B | $3.9B | ||
| Q4 24 | $4.8B | $3.8B | ||
| Q3 24 | $5.1B | $3.8B |
| Q2 26 | — | $6.9B | ||
| Q1 26 | — | $6.9B | ||
| Q4 25 | $9.2B | $6.9B | ||
| Q3 25 | $9.0B | $7.0B | ||
| Q2 25 | $8.8B | $6.9B | ||
| Q1 25 | $8.5B | $6.8B | ||
| Q4 24 | $8.7B | $6.7B | ||
| Q3 24 | $9.2B | $7.0B |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 0.48× | 0.45× | ||
| Q3 25 | 0.50× | 0.48× | ||
| Q2 25 | 0.52× | 0.46× | ||
| Q1 25 | 0.55× | 0.50× | ||
| Q4 24 | 0.53× | 0.52× | ||
| Q3 24 | 0.49× | 0.55× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $229.9M | — |
| Free Cash FlowOCF − Capex | $215.2M | $86.0M |
| FCF MarginFCF / Revenue | 20.5% | 21.6% |
| Capex IntensityCapex / Revenue | 1.4% | 4.4% |
| Cash ConversionOCF / Net Profit | 1.28× | — |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | $654.3M |
8-quarter trend — quarters aligned by calendar period.
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | $229.9M | $209.5M | ||
| Q3 25 | $355.1M | $203.5M | ||
| Q2 25 | $343.3M | $161.7M | ||
| Q1 25 | $169.4M | $105.7M | ||
| Q4 24 | $189.3M | $172.6M | ||
| Q3 24 | $367.0M | $205.3M |
| Q2 26 | — | $86.0M | ||
| Q1 26 | — | $189.8M | ||
| Q4 25 | $215.2M | $189.8M | ||
| Q3 25 | $341.4M | $188.7M | ||
| Q2 25 | $330.5M | $146.9M | ||
| Q1 25 | $153.9M | $91.4M | ||
| Q4 24 | $172.5M | $157.1M | ||
| Q3 24 | $350.6M | $191.6M |
| Q2 26 | — | 21.6% | ||
| Q1 26 | — | 46.6% | ||
| Q4 25 | 20.5% | 21.1% | ||
| Q3 25 | 32.5% | 21.5% | ||
| Q2 25 | 32.3% | 17.0% | ||
| Q1 25 | 15.3% | 11.2% | ||
| Q4 24 | 16.9% | 18.2% | ||
| Q3 24 | 35.5% | 24.0% |
| Q2 26 | — | 4.4% | ||
| Q1 26 | — | 15.6% | ||
| Q4 25 | 1.4% | 2.2% | ||
| Q3 25 | 1.3% | 1.7% | ||
| Q2 25 | 1.3% | 1.7% | ||
| Q1 25 | 1.5% | 1.8% | ||
| Q4 24 | 1.6% | 1.8% | ||
| Q3 24 | 1.7% | 1.7% |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 1.28× | 1.63× | ||
| Q3 25 | 1.90× | 1.59× | ||
| Q2 25 | 1.76× | 1.23× | ||
| Q1 25 | — | 1.11× | ||
| Q4 24 | 0.94× | 1.40× | ||
| Q3 24 | 2.05× | 1.72× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
IEX
Segment breakdown not available.
